Do analysts recommend BDRX or GOVX?

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 53,280.78%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, BDRX or GOVX?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 1.01 -$8.42M N/A N/A GeoVax Labs $2.49M 0.83 -$21.47M -$11.34 N/A

Is BDRX or GOVX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A GeoVax Labs N/A -743.64% -394.74%

Does the media refer more to BDRX or GOVX?

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 4 mentions for Biodexa Pharmaceuticals and 3 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 1.16 beat Biodexa Pharmaceuticals' score of 0.20 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BDRX or BCAB?

BioAtla has a consensus target price of $200.00, indicating a potential upside of 13,233.33%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, BDRX or BCAB?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 1.01 -$8.42M N/A N/A BioAtla $8.50M 0.29 -$59.61M -$25.45 N/A

Is BDRX or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A BioAtla N/A N/A -289.67%

Do analysts recommend BDRX or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BDRX or GNPX?

Biodexa Pharmaceuticals has higher revenue and earnings than Genprex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 1.01 -$8.42M N/A N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is BDRX or GNPX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Genprex N/A -163.12% -128.98%

Do analysts recommend BDRX or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BDRX or VBIO?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 1.01 -$8.42M N/A N/A Valion Bio, Inc. Common Stock $780K 2.44 -$8.88M -$159.25 N/A

Is BDRX or VBIO more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts rate LABT or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, LABT or BDRX?

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A Biodexa Pharmaceuticals $470K 1.01 -$8.42M N/A N/A

Is LABT or BDRX more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Biodexa Pharmaceuticals N/A N/A N/A

Biodexa Pharmaceuticals (BDRX) Competitors

$0.46 -0.06 (-12.13%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.46 0.00 (-0.04%)

As of 10/9/2026 07:39 PM Eastern

Compare

BDRX vs. GOVX, BCAB, GNPX, VBIO, and LABT

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? Biodexa Pharmaceuticals's main competitors and comparable companies include GeoVax Labs (GOVX), BioAtla (BCAB), Genprex (GNPX), Valion Bio, Inc. Common Stock (VBIO), and Lakewood-Amedex Biotherapeutics (LABT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biodexa Pharmaceuticals compare to GeoVax Labs?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Biodexa Pharmaceuticals' return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
GeoVax Labs	N/A	-743.64%	-394.74%

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 53,280.78%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biodexa Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.69, meaning that its stock price is 269% more volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 4 mentions for Biodexa Pharmaceuticals and 3 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 1.16 beat Biodexa Pharmaceuticals' score of 0.20 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodexa Pharmaceuticals has higher earnings, but lower revenue than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	1.01	-$8.42M	N/A	N/A
GeoVax Labs	$2.49M	0.83	-$21.47M	-$11.34	N/A

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Biodexa Pharmaceuticals beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to BioAtla?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Biodexa Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Biodexa Pharmaceuticals and 0 mentions for BioAtla. Biodexa Pharmaceuticals' average media sentiment score of 0.20 beat BioAtla's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
BioAtla	Neutral

BioAtla has a consensus target price of $200.00, indicating a potential upside of 13,233.33%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
BioAtla	N/A	N/A	-289.67%

Biodexa Pharmaceuticals has higher earnings, but lower revenue than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	1.01	-$8.42M	N/A	N/A
BioAtla	$8.50M	0.29	-$59.61M	-$25.45	N/A

Summary

Biodexa Pharmaceuticals and BioAtla tied by winning 6 of the 12 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Genprex?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Biodexa Pharmaceuticals has higher revenue and earnings than Genprex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	1.01	-$8.42M	N/A	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Biodexa Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Genprex	N/A	-163.12%	-128.98%

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biodexa Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Genprex has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 3 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Biodexa Pharmaceuticals and 1 mentions for Genprex. Genprex's average media sentiment score of 1.82 beat Biodexa Pharmaceuticals' score of 0.20 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Genprex	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biodexa Pharmaceuticals beats Genprex on 8 of the 9 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Valion Bio, Inc. Common Stock?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 4 mentions for Biodexa Pharmaceuticals. Valion Bio, Inc. Common Stock's average media sentiment score of 0.27 beat Biodexa Pharmaceuticals' score of 0.20 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodexa Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	1.01	-$8.42M	N/A	N/A
Valion Bio, Inc. Common Stock	$780K	2.44	-$8.88M	-$159.25	N/A

Summary

Valion Bio, Inc. Common Stock beats Biodexa Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 4 mentions for Biodexa Pharmaceuticals. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.69 beat Biodexa Pharmaceuticals' score of 0.20 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Biodexa Pharmaceuticals	N/A	N/A	N/A

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A
Biodexa Pharmaceuticals	$470K	1.01	-$8.42M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lakewood-Amedex Biotherapeutics beats Biodexa Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$470K	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	N/A	13.55	275.01	26.14
Price / Sales	1.01	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.00	17.17	11.22	6.33
Net Income	-$8.42M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-25.76%	-1.34%	-0.89%	-1.40%
1 Month Performance	-64.60%	-8.04%	-4.02%	-3.35%
1 Year Performance	-99.00%	14.18%	7.13%	1.49%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.902 of 5 stars	$0.46 -12.1%	N/A	-99.0%	$470K	$470K	N/A	11	News Coverage Short Interest Decrease
GOVX GeoVax Labs	3.5689 of 5 stars	$0.29 -9.8%	$150.00 +51,893.1%	-98.0%	$2.36M	$2.49M	N/A	19	Positive News Short Interest Decrease Gap Down
BCAB BioAtla	1.0515 of 5 stars	$1.35 +2.3%	$200.00 +14,714.8%	-96.5%	$2.25M	$8.50M	N/A	60	Gap Up
GNPX Genprex	0.4741 of 5 stars	$2.61 -4.0%	N/A	-98.8%	$2.23M	N/A	N/A	13	Gap Up
VBIO Valion Bio, Inc. Common Stock	0.2371 of 5 stars	$2.38 -4.0%	N/A	-97.0%	$2.20M	N/A	N/A	10	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. GOVX, BCAB, GNPX, VBIO, and LABT

How does Biodexa Pharmaceuticals compare to GeoVax Labs?

Summary

How does Biodexa Pharmaceuticals compare to BioAtla?

Summary

How does Biodexa Pharmaceuticals compare to Genprex?

Summary

How does Biodexa Pharmaceuticals compare to Valion Bio, Inc. Common Stock?

Summary

How does Biodexa Pharmaceuticals compare to Lakewood-Amedex Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. GOVX, BCAB, GNPX, VBIO, and LABT

How does Biodexa Pharmaceuticals compare to GeoVax Labs?

Is BDRX or GOVX more profitable?

Do analysts recommend BDRX or GOVX?

Which has more volatility and risk, BDRX or GOVX?

Does the media refer more to BDRX or GOVX?

Which has better earnings & valuation, BDRX or GOVX?

Do institutionals and insiders have more ownership in BDRX or GOVX?

Summary

How does Biodexa Pharmaceuticals compare to BioAtla?

Which has more volatility and risk, BDRX or BCAB?

Does the media refer more to BDRX or BCAB?

Do analysts prefer BDRX or BCAB?

Do insiders and institutionals have more ownership in BDRX or BCAB?

Is BDRX or BCAB more profitable?

Which has stronger valuation and earnings, BDRX or BCAB?

Summary

How does Biodexa Pharmaceuticals compare to Genprex?

Which has higher valuation and earnings, BDRX or GNPX?

Is BDRX or GNPX more profitable?

Do insiders and institutionals hold more shares of BDRX or GNPX?

Which has more risk & volatility, BDRX or GNPX?

Does the media refer more to BDRX or GNPX?

Do analysts recommend BDRX or GNPX?

Summary

How does Biodexa Pharmaceuticals compare to Valion Bio, Inc. Common Stock?

Is BDRX or VBIO more profitable?

Does the media favor BDRX or VBIO?

Which has more volatility & risk, BDRX or VBIO?

Do analysts recommend BDRX or VBIO?

Do institutionals & insiders have more ownership in BDRX or VBIO?

Which has better valuation & earnings, BDRX or VBIO?

Summary

How does Biodexa Pharmaceuticals compare to Lakewood-Amedex Biotherapeutics?

Does the media refer more to LABT or BDRX?

Is LABT or BDRX more profitable?

Which has better earnings & valuation, LABT or BDRX?

Do analysts rate LABT or BDRX?

Do institutionals and insiders hold more shares of LABT or BDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools